Cancer is a global public health concern. Alterations in epigenetic processes are among the
earliest genomic aberrations occurring during cancer development and are closely related …

DNA methylation is a stable but not irreversible epigenetic signal that silences gene
expression. It has a variety of important functions in mammals, including control of gene …

The DNA methyltransferase (DNMT) inhibitors azacytidine and decitabine are the most
successful epigenetic drugs to date and are still the most widely used as epigenetic …

Background: Gene silencing by abnormal methylation of promoter regions of regulatory
genes is commonly associated with cancer. Silenced tumor suppressor genes are obvious …

Mechanism-based inhibitors of enzymes, which mimic reactive intermediates in the reaction
pathway, have been deployed extensively in the analysis of metabolic pathways and as …

The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues,
azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy …

The frequent silencing of tumor suppressor genes by altered cytosine methylation and
chromatin structural changes makes this process an attractive target for epigenetic therapy …

In addition to the genetic alterations, observed in cancer cells, are mitotically heritable
changes in gene expression not encoded by the DNA sequences, which are referred to as …

DNA methylation is an essential modification of DNA in mammals that is involved in gene
regulation, development, genome defence and disease. In mammals 3 families of DNA …

The major goal of epigenetic therapy is to reverse aberrant promoter hypermethylation and
restore normal function of tumor suppressor genes by the use of chromatin-modifying drugs …